ClinicalTrials.gg
RecruitingNCT07110038Updated Oct 13, 2026

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

A Phase 2 interventional study of Avelumab and enfortumab vedotin in Penile Squamous Cell Carcinoma (PSCC), sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 9 sites in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 13, 2026Sponsor changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.

02

Conditions studied

  • Penile Squamous Cell Carcinoma (PSCC)
03

In context

Lead sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest is the lead sponsor of 64 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has ability to understand and the willingness to sign a written .
  2. Patient is ≥ 18 years of age at time of signing the written informed consent.
  3. Male patients with confirmed diagnosis of penile squamous cell carcinoma.
  4. Patients must be considered non-eligible for curative surgical management. Eligibility for trial inclusion should be based on the presence of either distant disease (M1) or at least one of the following scenarios based on the UICC/AJCC 8th edition TNM clinical and pathological classification of penile cancer:

    1. Stage 3 (cT3) disease with a single lymph node involved (N1).
    2. Stage 4 disease (cT4).
    3. Any T stage with either N2 (involvement of multiple or bilateral inguinal nodes) or N3 (fixed inguinal nodal mass or pelvic lymphadenopathy) disease. Patients without distant metastases are eligible if multidisciplinary team review concludes that they are unsuitable for curative surgery.
  5. Tumor material (archival or current) is available for local pathology testing (, HPV).
  6. (ECOG) performance status of ≤ 2.
  7. per 1.1 criteria.
  8. No prior systemic therapy for metastatic or locally advanced PeCa in the palliative setting. NOTE: (Neo) systemic therapy (without IO) is allowed at least 6 months before study enrollment.
  9. Patients has adequate blood count, liver-enzymes, and renal function:

    1. (Absolute neutrophil count) > 1,500 cells/μL without the use of hematopoietic growth factors.
    2. count ≥ 100 x 109/L (>100,000 per mm3).
    3. ≥ 9 g/dL.
    4. Serum total ≤ 1.5x institutional upper normal limit ().
    5. (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN (or ≤ 5 x ULN if liver metastases are present).
    6. ≥ 30 mL/min as calculated by the Cockcroft- Gault equation (or local institutional standard method).
  10. No other active within the past 3 years, except for adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin.
  11. No history of significant cardiovascular disease (e.g., myocardial infarction, unstable angina) within the last 6 months.
  12. of at least 3 months.
  13. Willingness to comply with study requirements, including follow-up visits and procedures.
  14. Patients with female partners of must agree to use an effective method of during the study and for 4 months after the last dose of enfortumab vedotin or for at least 30 days after last avelumab treatment administration, whichever occurs last.

Exclusion criteria

Exclusion Criteria:

  1. Previous systemic therapy for or locally advanced PeCa in the palliative setting.
  2. Previous treatment with drugs or devices within 30 days prior to the first dose of trial treatment.
  3. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  4. Active, known, or suspected disease requiring systemic treatment within the past 2 years. Patients with controlled autoimmune d disease not requiring systemic treatment including diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases are eligible.
  5. Has ongoing sensory or motor neuropathy Grade 2 or higher.
  6. Has a history of uncontrolled diabetes ( > 8%).
  7. (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ Classification Class II), or serious cardiac arrhythmia requiring medication.
  8. Active infection requiring systemic therapy. The following exceptions apply:

    1. Patients with an infection are eligible if they are on effective antiretroviral therapy with undetectable viral load within 6 months, provided there is no expected drug-drug interaction.
    2. Patients with evidence of chronic infection are eligible if the HBV viral load is undetectable on suppressive therapy (if indicated), and if they have , AST, and total levels \< , and provided there is no expected drug-drug interaction.
    3. Patients with a history of infection are eligible if they have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load, and if they have ALT, AST, and total bilirubin levels \< ULN.
  9. History of other within the past 3 years, with the exception of adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin.
  10. Severe hepatic impairment ( Class C).
  11. Severe renal impairment or requirement for dialysis.
  12. History of keratitis and corneal ulceration in the last two years.
  13. Active pneumonia, pneumonitis or pulmonary fibrosis.
  14. Active tuberculosis.
  15. Known prior severe to the study drugs or any component of their formulations, known severe hypersensitivity reactions to monoclonal antibodies (NCT Grade ≥ 3).
  16. Inability or unwillingness to comply with study requirements, including follow-up visits and procedures.
  17. Inability to provide .
  18. Use of immunosuppressive medication within 14 days prior to the first dose of study treatment, with the exception of intranasal, inhaled, topical , or local steroid injections (e.g., intra-articular injection), systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent, or steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
  19. Prior organ transplantation including allogenic stem-cell transplantation.
  20. Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
  21. Persisting toxicity related to prior therapy (NCI CTCAE Grade > 1); however, alopecia or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
  22. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
  23. Patient participated in another interventional clinical study according to Medicines Act within 28 days prior to study enrollment or participation in a clinical study according to Medicines Act at the same time as this study unless it is an observational / non-interventional study or during the follow- up period of an interventional study.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Combined therapy consisting of enfortumab vedotin and avelumab

    Drug: Avelumab · Drug: enfortumab vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (ORR) in 1st line as assessed by investigators, defined as the proportion of patients achieving a complete response (CR) or partial response (PR) according to RECIST 1.1 criteria.

    Time frame: Up to 24 months.

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS), defined as the time from the start of treatment to the first documented disease progression acc. to RECIST 1.1 criteria or death from any cause, whichever occurs first.

    Time frame: Up to 5 years.

  2. Overall Survival (OS)

    Time from the start of treatment to death from any cause.

    Time frame: Up to 5 years.

  3. Duration of Response (DoR)

    Time from the first documented response (CR or PR) to disease progression or death from any cause (whichever occurs first).

    Time frame: Up to 5 years.

  4. Disease Control Rate (DCR)

    Disease Control Rate (DCR), defined as the proportion of patients achieving CR, PR, or stable disease (SD) according to RECIST 1.1 criteria.

    Time frame: Up to 27 months.

  5. Incidence and severity of (serious) adverse events

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to 27 months

  6. Quality of life (QoL) using EQ-5D-5L questionnaire

    Changes in patient-reported quality of life, using EQ-5D-5L questionnaire and a set of bolt-on questions will be collected.

    Time frame: Up to 24 months.

  7. Quality of life (QoL) using EQ-HWB-S questionnaire

    Changes in patient-reported quality of life, using EQ-HWB-S questionnaire and a set of bolt-on questions will be collected.

    Time frame: Up to 24 months.

07

Study locations

9 of 9 sites recruiting
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Germany
    Recruiting
    • Christian Thomas, Prof. Dr. · Principal investigator
  • University Hospital and Medical Faculty, Heinrich-Heine-University, Düsseldorf
    Düsseldorf, Germany
    Recruiting
    • Günter Niegisch, Prof. Dr. · Principal investigator
  • University Medical Center of Johannes Gutenberg-University
    Mainz, Germany
    Recruiting
    • Anita Thomas, PD Dr. · Principal investigator
  • University Hospital Mannheim
    Mannheim, Germany
    Recruiting
    • Benjamin Meister, Dr. · Principal investigator
  • Technical University of Munich, University Hospital Munich
    Munich, Germany
    Recruiting
    • Margitta Retz, Prof. Dr. · Principal investigator
  • University Hospital Munich
    München, Germany
    Recruiting
    • Nikolaos Pyrgidis, PD Dr. · Principal investigator
  • Caritas St. Josef Medical Center
    Regensburg, Germany
    Recruiting
    • Marco Schnabel, PD Dr. · Principal investigator
  • Rostock University Medical Center
    Rostock, Germany
    Recruiting
    • Angelika Borkowetz, Prof. Dr. · Principal investigator
  • University Hospital Tübingen
    Tübingen, Germany
    Recruiting
    • Igor Tsaur, Prof. Dr. · Contact
    • Igor Tsaur, Prof. Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2029, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Aug 7, 2025
StartActual
Dec 16, 2025
Primary completionEst.
May 2029
CompletionEst.
Nov 2030
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • University Hospital Munich · München, Germany
Oct 13, 2026
Sponsor
Collaborators added: University Hospital Tuebingen; collaborators removed: University Hospital Tübingen
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added
    Show site
    • University Hospital Munich · München, Germany
    Sponsor Collaborators added: University Hospital Tuebingen; collaborators removed: University Hospital Tübingen
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07110038
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Dec 16, 2025
Primary completion
May 2029 (estimated)
Completion
Nov 2030 (estimated)
Last update
Oct 13, 2026

Study contacts

Igor Tsaur, Prof. Dr.
Contact
igor.tsaur@med.uni-tuebingen.de
+49 7071-29-86000
Claudia Pauligk, Dr.
Contact
depeca-1@ikf-khnw.de
+49 69 5899 787 52
Salah-Eddin Al-Batran, Prof. Dr.
study chair · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avelumab · Enfortumab vedotin

Start the discussion